Cargando…
PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL.
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431502/ http://dx.doi.org/10.1097/01.HS9.0000850384.35364.fa |
| _version_ | 1784780072751726592 |
|---|---|
| author | Burger, J. Sivina, M. Kim, E. Issa, G. Wierda, W. Jain, N. Thompson, P. Ferrajoli, A. |
| author_facet | Burger, J. Sivina, M. Kim, E. Issa, G. Wierda, W. Jain, N. Thompson, P. Ferrajoli, A. |
| author_sort | Burger, J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431502 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94315022022-08-31 PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL. Burger, J. Sivina, M. Kim, E. Issa, G. Wierda, W. Jain, N. Thompson, P. Ferrajoli, A. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431502/ http://dx.doi.org/10.1097/01.HS9.0000850384.35364.fa Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Burger, J. Sivina, M. Kim, E. Issa, G. Wierda, W. Jain, N. Thompson, P. Ferrajoli, A. PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL. |
| title | PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL. |
| title_full | PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL. |
| title_fullStr | PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL. |
| title_full_unstemmed | PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL. |
| title_short | PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL. |
| title_sort | pb1883: time-limited treatment with acalabrutinib plus obinotuzumab in treatment-naïve chronic lymphocytic leukemia patients induces deep remissions: early results of an ongoing phase 2 trial. |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431502/ http://dx.doi.org/10.1097/01.HS9.0000850384.35364.fa |
| work_keys_str_mv | AT burgerj pb1883timelimitedtreatmentwithacalabrutinibplusobinotuzumabintreatmentnaivechroniclymphocyticleukemiapatientsinducesdeepremissionsearlyresultsofanongoingphase2trial AT sivinam pb1883timelimitedtreatmentwithacalabrutinibplusobinotuzumabintreatmentnaivechroniclymphocyticleukemiapatientsinducesdeepremissionsearlyresultsofanongoingphase2trial AT kime pb1883timelimitedtreatmentwithacalabrutinibplusobinotuzumabintreatmentnaivechroniclymphocyticleukemiapatientsinducesdeepremissionsearlyresultsofanongoingphase2trial AT issag pb1883timelimitedtreatmentwithacalabrutinibplusobinotuzumabintreatmentnaivechroniclymphocyticleukemiapatientsinducesdeepremissionsearlyresultsofanongoingphase2trial AT wierdaw pb1883timelimitedtreatmentwithacalabrutinibplusobinotuzumabintreatmentnaivechroniclymphocyticleukemiapatientsinducesdeepremissionsearlyresultsofanongoingphase2trial AT jainn pb1883timelimitedtreatmentwithacalabrutinibplusobinotuzumabintreatmentnaivechroniclymphocyticleukemiapatientsinducesdeepremissionsearlyresultsofanongoingphase2trial AT thompsonp pb1883timelimitedtreatmentwithacalabrutinibplusobinotuzumabintreatmentnaivechroniclymphocyticleukemiapatientsinducesdeepremissionsearlyresultsofanongoingphase2trial AT ferrajolia pb1883timelimitedtreatmentwithacalabrutinibplusobinotuzumabintreatmentnaivechroniclymphocyticleukemiapatientsinducesdeepremissionsearlyresultsofanongoingphase2trial |